Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC
Phase 3negativeSacituzumab govitecanPembrolizumabNegative
AI Analysis
Summary
Sacituzumab govitecan plus pembrolizumab failed to meet primary endpoints in the Phase 3 EVOKE-03/KEYNOTE-D46 trial for first-line PD-L1-high metastatic NSCLC, despite showing numerically longer PFS and higher response rates without statistical significance in OS benefit.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Sacituzumab govitecan plus pembrolizumab did not meet primary endpoints. Numerically longer progression-free survival and higher response rates observed, but no statistically significant PFS or OS benefit achieved.
Importance:8/10
Sentiment:
-0.85
Phase 3 failureNSCLCImmuno-oncologyPrimary endpoint missCombination therapy
Read the original article
Published by PR Newswire Biotech on September 13, 2026 11:50 AM